AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02612805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
Study NCT02612805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined training
Description: Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed.
Study NCT02612805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training placebo
Description: Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
Study NCT03659890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low nucleotide
Description: 2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
Study NCT03659890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High nucleotide
Description: 2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
Study NCT03659890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High nucletide + Ribose
Description: 2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
Study NCT03721978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: 1 milliliter (mL) VGX-3100 injected IM.
Study NCT03721978 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: 1 mL of matched Placebo injected IM.
Study NCT03721978 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA™-5PSP
Description: CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
Study NCT03721978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™-5PSP
Description: CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
Study NCT02459236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-301
Description: CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
Study NCT03179800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD
Description: The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
Study NCT03179800 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Implantation
Description: Sham Implantation
Study NCT01971606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.
Study NCT01971606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.
Study NCT03535584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
Study NCT03619941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Juice
Description: 100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar.
Study NCT03619941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
Study NCT01034579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
Study NCT01034579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
Study NCT01763788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV
Study NCT01763788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV
Study NCT01763788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT01763788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV
Study NCT01763788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV
Study NCT01190332 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: endoscopic sphincterotomy by conventional method
Study NCT01190332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic sphincterotomy by rendezvous method
Study NCT00717678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf-XL
Description: oral
Study NCT00717678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT00717678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: oral
Study NCT00717678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: oral
Study NCT01899274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bant iPhone application
Study NCT01321398 — intervention group
Intervention type: OTHER
Intervention: Esophageal Pressure Monitoring
Description: An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
Study NCT02459236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02375880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administered by IV infusion.
Study NCT02375880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Administered by IV infusion
Study NCT01950559 — intervention group
Intervention type: OTHER
Intervention: Oral food challenge
Description: Oral food challenge to determine allergy to soy
Study NCT01064505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPI-1007 at various doses
Description: Single Intravitreal Injection
Study NCT01623206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion.
Study NCT01886391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Retraining
Description: Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 \[5-min DBR\], 1 for week 2 \[10-min DBR\], 1 for weeks 3-8 \[15-min DBR\]), developed by the PI, to use to practice their deep breathing.
Study NCT01902381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study NCT02790359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: Group of patients who would receive air insufflation
Study NCT02790359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide
Description: Group of patients who would receive carbon dioxide insufflation
Study NCT01881997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Intramuscular (IM), 1ugm/kg, x1
Study NCT00837096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C. Therapy
Description: Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
Study NCT00837096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moist wound therapy (MWT)
Description: Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
Study NCT02394509 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
Study NCT02394509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
Study NCT01521689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Low doses of sub cutaneaous rituximab
Study NCT04514796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: SB5 (adalimumab), 40 mg, single-dose
Study NCT04514796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: SB5 (adalimumab), 40 mg, single-dose
Study NCT00515697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
Study NCT01881997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IM normal saline
Study NCT03337581 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexmedetomidine
Description: see arms
Study NCT03337581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: see arms
Study NCT01111136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress intervention
Description: To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
Study NCT03338257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Husky Reads Intervention
Description: The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
Study NCT02160678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
Study NCT02160678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream, 0.1 %
Description: Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
Study NCT02160678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tazorac Cream, 0.1%
Description: Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
Study NCT01565239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiix prothrombin time
Description: The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
Study NCT01565239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiix prothrombin time
Description: The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
Study NCT04493983 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic salpingo-oophorectomy
Description: Laparoscopic bilateral salpingo-oophorectomy
Study NCT04493983 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic bilateral salpingo-oophorectomy
Description: Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
Study NCT03805451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Steps for PrEP for Youth
Description: Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
Study NCT04106050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.
Study NCT04106050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm.
Study NCT04106050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT04106050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Administered as specified in the treatment arm.
Study NCT01011166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
Study NCT01011166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
Study NCT01011166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
Study NCT01011166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
Study NCT03602391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCP Plus
Description: The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
Study NCT03991013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50 mg
Description: Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
Study NCT01928407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARUNAVIR
Description: The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
Study NCT01928407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATAZANAVIR
Description: The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
Study NCT03207620 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: using serum periostin and eotaxin-2 level
Description: collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
Study NCT03207620 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: airway corticosteroid sensitivity
Description: each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
Study NCT00111839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
Study NCT00111839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
Study NCT00111839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matuzumab
Description: Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
Study NCT01863537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia Connect
Study NCT01863537 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Connect